StreetAlpha.app
Home › Stocks › PVLA

Palvella Therapeutics, Inc. (PVLA)

Healthcare
$144.35
▼ −0.17%
LAST CLOSE · NOV 17

Palvella Therapeutics develops topical drug candidates for rare skin diseases and vascular malformations, aimed at patients and their doctors. It last closed at $144.35 on Nov 17, down 0.17% on the day. The average 12-month price target from 5 analysts is $237.80 (+64.7% from the last close), with a high of $246.00 and a low of $228.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in PVLA, 33% of them bullish and 67% bearish. In the past 30 days there were 1 dark pool print totaling $1.2M, the largest $1.2M.

AI Auto Pilots
Is PVLA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$75.0M
EPS (diluted)
−$5.53
Valuation
Market cap
$2.1B
14.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$193.3M
At Sep 30
Shareholder equity
$197.9M
Shares outstanding
14.6M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$45.7M−$45.7MFY2021FY2022: −$33.3M−$33.3MFY2022FY2023: $18.7M$18.7MFY2023FY2024: −$17.4M−$17.4MFY2024FY2025: −$41.7M−$41.7MFY2025

From PVLA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
5 Buy0 Hold0 Sell
Each firm's latest rating on PVLA in the past 90 days
Average 12-month target
$237.80
▲ 64.7% upside

Based on 5 analysts who set a price target on PVLA in the past 90 days. The average target is $237.80, with a high of $246.00 and a low of $228.00, compared with the last close of $144.35.

Low $228.00Avg $237.80High $246.00
Blue marker: last close $144.35
Highest target$246.00
Average target$237.80
Lowest target$228.00
Latest rating changes
Leerink PartnersInitiated
Nov 16Buy$228
Canaccord GenuityMaintained
Nov 9Buy$243
OppenheimerMaintained
Nov 6Buy$232
HC Wainwright & Co.Maintained
Oct 12Buy$246
Chardan CapitalMaintained
Sep 21Buy$240
DateFirmActionRatingPrice target
Nov 16Leerink PartnersInitiatedBuy$228
Nov 9Canaccord GenuityMaintainedBuy$243
Nov 6OppenheimerMaintainedBuy$232
Oct 12HC Wainwright & Co.MaintainedBuy$246
Sep 21Chardan CapitalMaintainedBuy$240
Loading…

Technical Analysis

PVLA · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 9% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 47). The nearest support is the swing low (Aug 31) at $143.47, and the nearest resistance the Pivot R1 at $145.79.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 6.5%/day
Key levels
$179.9552 week high+24.7%
$152.80Swing high (Jul 9)+5.9%
$148.9020 day average+3.2%
$145.80100 day average+1.0%
$145.79Pivot R1+1.0%
$144.35Last close
$143.47Swing low (Aug 31)−0.6%
$143.27Pivot−0.7%
$143.1550 day average−0.8%
$141.84Pivot S1−1.7%
$131.10200 day average−9.2%
$72.2252 week low−50.0%
Indicators
RSI (14)47.01Middle of its rangeNeutral
MACD4.22Below its signal lineBearish
Stochastic27.8Middle of its rangeNeutral
ADX (14)27.1Trending down
Williams %R-90.8Oversold below −80, overbought above −20Oversold
CCI (20)-27.6Oversold below −100, overbought above 100Neutral
Rate of change−5.6%Change over 10 sessionsBearish
ATR (14)$9.45Typical daily range, 6.5% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Above
What happened before, for PVLA

What happened before

See how PVLA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bearish1 bullish and 2 bearish whale options trades in the last 90 days. See Whale Flow

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D
Total alerts
3
Bullish
1
33%
Bearish
2
67%
Date span
Sep 17 – Nov 9
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$1.2M
Largest print
$1.2M
Loading…

PVLA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 81 selling
  • ▲Held by funds +3.3 pts
  • ▲Funds holding +2
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding199197+1.0%
In funds' top 10660.0%
Held by funds99.7%96.4%+3.3 pts
New / increased30 / 7735 / 89−13.7%
Reduced / sold out53 / 2843 / 19+30.6%
Put/call ratio0.112.00−94.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PVLA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PVLA is in one of them and how their past PVLA trades turned out.

PVLA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PVLA in an article yet. Here's the latest on the wider market.

About Palvella Therapeutics

Palvella Therapeutics is a biopharmaceutical company based in Wayne, Pennsylvania, that is developing topical treatments for rare skin diseases and vascular malformations where no approved therapies exist. Its lead candidate, a rapamycin gel called QTORIN rapamycin, is in clinical trials for microcystic lymphatic malformations and cutaneous venous malformations. The company also has a candidate in development for disseminated superficial actinic porokeratosis. Its target customers are patients with these conditions and the physicians who treat them.

Headquarters
Wayne, PA